GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akebia Therapeutics Inc (STU:AX9) » Definitions » 5-Year Yield-on-Cost %

Akebia Therapeutics (STU:AX9) 5-Year Yield-on-Cost % : 0.00 (As of May. 26, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Akebia Therapeutics 5-Year Yield-on-Cost %?

Akebia Therapeutics's yield on cost for the quarter that ended in Mar. 2024 was 0.00.


The historical rank and industry rank for Akebia Therapeutics's 5-Year Yield-on-Cost % or its related term are showing as below:



STU:AX9's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.8
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Akebia Therapeutics's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, Akebia Therapeutics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akebia Therapeutics's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akebia Therapeutics's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Akebia Therapeutics's 5-Year Yield-on-Cost % falls into.



Akebia Therapeutics 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Akebia Therapeutics is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Akebia Therapeutics  (STU:AX9) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Akebia Therapeutics 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Akebia Therapeutics's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Akebia Therapeutics (STU:AX9) Business Description

Traded in Other Exchanges
Address
245 First Street, Cambridge, MA, USA, 02142
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes 1) Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease. 2) Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients. 3) HIF-PH inhibitors in preclinical development.

Akebia Therapeutics (STU:AX9) Headlines

No Headlines